Structure Therapeutics Net Income From Continuing Ops Over Time
| GPCR Stock | 75.98 2.57 3.27% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Structure Therapeutics Performance and Structure Therapeutics Correlation. Structure | Build AI portfolio with Structure Stock |
Can Biotechnology industry sustain growth momentum? Does Structure have expansion opportunities? Factors like these will boost the valuation of Structure Therapeutics. Market participants price Structure higher when confident in its future expansion prospects. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Structure Therapeutics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Understanding Structure Therapeutics requires distinguishing between market price and book value, where the latter reflects Structure's accounting equity. The concept of intrinsic value - what Structure Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Market sentiment, economic cycles, and investor behavior can push Structure Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Structure Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Structure Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Structure Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income From Continuing Ops Analysis
Compare Structure Therapeutics and related stocks such as Edgewise Therapeutics, Viridian Therapeutics, and Uniqure NV Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EWTX | (9.7 M) | (9.7 M) | (9.7 M) | (9.7 M) | (9.7 M) | (9.7 M) | (9.7 M) | (9.7 M) | (9.7 M) | (9.7 M) | (17.1 M) | (42.8 M) | (67.6 M) | (100.2 M) | (133.8 M) | (120.4 M) | (114.4 M) |
| VRDN | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (26.5 M) | (32.7 M) | (41.9 M) | (110.7 M) | (79.6 M) | (130.1 M) | (216.7 M) | (269.9 M) | (243 M) | (230.8 M) |
| QURE | (26.8 M) | (26.8 M) | (26.8 M) | (26.8 M) | (49.8 M) | (82.1 M) | (73.4 M) | (79.3 M) | (83.3 M) | (124.2 M) | (125 M) | 329.6 M | (126.8 M) | (228.5 M) | (239.6 M) | (215.6 M) | (204.8 M) |
| OCUL | (28.6 M) | (28.6 M) | (28.6 M) | (28.6 M) | (28.6 M) | (39.7 M) | (44.7 M) | (63.4 M) | (60 M) | (86.4 M) | (155.6 M) | (6.6 M) | (71 M) | (67.1 M) | (193.5 M) | (265.9 M) | (252.6 M) |
| NUVB | (41.7 M) | (41.7 M) | (41.7 M) | (41.7 M) | (41.7 M) | (41.7 M) | (41.7 M) | (41.7 M) | (41.7 M) | (41.7 M) | (41.7 M) | (86.8 M) | (104.2 M) | (75.8 M) | (567.9 M) | (511.1 M) | (485.6 M) |
| GLPG | (16.8 M) | (16.8 M) | (16.8 M) | (16.8 M) | (37.3 M) | (194.3 M) | 54 M | (115.7 M) | (29.3 M) | 149.8 M | (311 M) | (125.4 M) | (218 M) | (153.1 M) | (1.3 M) | (1.2 M) | (1.2 M) |
| MESO | (75.5 M) | (75.5 M) | (75.5 M) | (75.5 M) | (96.2 M) | (4.1 M) | (76.8 M) | (35.3 M) | (89.8 M) | (77.9 M) | (98.8 M) | (91.3 M) | (81.9 M) | (88 M) | (102.1 M) | (91.9 M) | (96.5 M) |
| LQDA | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (29.2 M) | (53.1 M) | (47.6 M) | (59.8 M) | (34.6 M) | (41 M) | (57.6 M) | (130.4 M) | (117.4 M) | (111.5 M) |
| CLDX | (44.8 M) | (44.8 M) | (59.1 M) | (81.5 M) | (118.1 M) | (127.2 M) | (128.5 M) | (93 M) | (151.2 M) | (50.9 M) | (59.8 M) | (70.5 M) | (112.3 M) | (124.6 M) | (157.9 M) | (142.1 M) | (149.2 M) |
| ABCL | 308.9 K | 308.9 K | 308.9 K | 308.9 K | 308.9 K | 308.9 K | 308.9 K | 308.9 K | 308.9 K | (2.2 M) | 118.9 M | 153.5 M | 158.5 M | (146.4 M) | (162.9 M) | (146.6 M) | (139.2 M) |
Structure Therapeutics and related stocks such as Edgewise Therapeutics, Viridian Therapeutics, and Uniqure NV Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Structure Therapeutics American | GPCR |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 601 Gateway Boulevard, |
| Exchange | NASDAQ Exchange |
null 75.98
Additional Tools for Structure Stock Analysis
When running Structure Therapeutics' price analysis, check to measure Structure Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Structure Therapeutics is operating at the current time. Most of Structure Therapeutics' value examination focuses on studying past and present price action to predict the probability of Structure Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Structure Therapeutics' price. Additionally, you may evaluate how the addition of Structure Therapeutics to your portfolios can decrease your overall portfolio volatility.